Journal
RHEUMATOLOGY INTERNATIONAL
Volume 36, Issue 12, Pages 1649-1656Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00296-016-3569-1
Keywords
Annexin A2; Antiphospholipid antibodies; Primary antiphospholipid syndrome; Tumor necrosis factor alpha
Categories
Ask authors/readers for more resources
Antiphospholipid syndrome (APS) is characterized by thromboses and/or pregnancy losses. Laboratory criterion for the diagnosis of APS is the presence of antiphospholipid antibodies (anticardiolipin, anti-beta2-glycoprotein I (a beta 2gpI) and lupus anticoagulant). On the one hand, the latest classification criteria for the diagnosis of APS emphasized that thrombotic manifestations of the syndrome should be without any signs of an inflammatory process, while on the other hand, some recent reports have suggested that APS is a pro-inflammatory state. This article is focused on the importance of TNF-alpha and annexin A2 (anxA2) for patients with vascular (thrombotic) manifestations of the primary APS. The classic antithrombotic and antiplatelet therapy does not protect APS patients from the development of recurrent thrombosis. Therefore, an urgent need for the introduction of new therapeutic approaches in the treatment of APS patients is obvious. This review provides a rationale for the necessity for the use of immunomodulatory medications that could interfere with beta 2gpI binding to its receptor(s), such as anxA2, and/or inhibit TNF-alpha activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available